Biofidelity Prepares to Launch Lung Cancer Mutation Detection Assay

CEO Barnaby Balmforth speaks with GenomeWeb about the unique biochemistry behind Biofidelity's ASPYRE technology and the advantages it can offer over sequencing-based assays – including simplicity, low cost, high sensitivity and faster turnaround times.

Read on GenomeWeb